One-Shot eye injection aims to halt rare genetic vision loss
NCT ID NCT07185256
Summary
This early-stage study is testing a one-time gene therapy injection for two rare, inherited eye diseases that cause progressive vision loss: Best vitelliform macular dystrophy (BVMD) and Autosomal-Recessive Bestrophinopathy (ARB). Researchers will give the experimental drug, OPGx-BEST1, to 10 adult participants to first check if it's safe and to find the best dose. The main goal is to see if a single injection into the eye can help control the disease over five years of follow-up.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ARB are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Children's Hospital Los Angeles
RECRUITINGLos Angeles, California, 90027, United States
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Cincinnati Eye Institute
RECRUITINGCincinnati, Ohio, 45242, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
Retina Foundation of the Southwest
RECRUITINGDallas, Texas, 75231, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
Vitreo Retinal Associates
NOT_YET_RECRUITINGGainesville, Florida, 34481, United States
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.